We are live on ! Find out more
BIOL

Biolase, Inc.
BIOL

Delisted

BIOL was delisted on the 18th of June, 2024.

Back to rankings

17 hedge funds and large institutions have $3.59M invested in Biolase, Inc. in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

6% more funds holding

Funds holding: 16 → 17 (+1)

6% more capital invested

Capital invested by funds: $3.39M → $3.59M (+$196K)

Holders
17
Holders Change
+1
Holders Change %
+6.25%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
6
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$211K
2
EIM
Essex Investment Management
Massachusetts
+$161K
3
PCM
Perkins Capital Management
Minnesota
+$55.2K
4
UBS Group
UBS Group
Switzerland
+$20.4K
5
TRCT
Tower Research Capital (TRC)
New York
+$2.8K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$62.4K
2
Citadel Advisors
Citadel Advisors
Florida
-$33.2K
3
BlackRock
BlackRock
New York
-$1.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$1.7M +$211K +529 +8%
Vanguard Group
2
Vanguard Group
Pennsylvania
$668K – – –
PCM
3
Perkins Capital Management
Minnesota
$321K +$55.2K +138 +12%
BlackRock
4
BlackRock
New York
$302K -$1.2K -3 -0.2%
EIM
5
Essex Investment Management
Massachusetts
$256K +$161K +404 +62%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$133K – – –
Renaissance Technologies
7
Renaissance Technologies
New York
$46K +$2.4K +6 +3%
Citadel Advisors
8
Citadel Advisors
Florida
$43K -$33.2K -83 -32%
State Street
9
State Street
Massachusetts
$42K – – –
Northern Trust
10
Northern Trust
Illinois
$27K – – –
Morgan Stanley
11
Morgan Stanley
New York
$21K -$62.4K -156 -65%
UBS Group
12
UBS Group
Switzerland
$14K +$20.4K +51 +1,020%
OCM
13
Orion Capital Management
California
$5K – – –
TRCT
14
Tower Research Capital (TRC)
New York
$5K +$2.8K +7 +54%
IA
15
IFP Advisors
Florida
$4K – – –
APA
16
American Portfolios Advisors
New York
$39 – – –
Bank of America
17
Bank of America
North Carolina
– +$400 +1 New

BIOL Hedge Fund Activity: Q3 2022 in Review

17 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q3 2022, worth a combined $3.59M — up 5.8% from $3.39M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new BIOL positions and 0 closed out — a net gain of 1 holder — while 6 added to existing stakes and 3 trimmed.

The largest buyer was Armistice Capital, adding an estimated $211K. The largest seller was Morgan Stanley, cutting an estimated $62.4K.

  • 17 institutional investors held Biolase, Inc. (BIOL) as of Q3 2022, up from 16 in Q2 2022.
  • Funds reported $3.59M of Biolase, Inc. stock for Q3 2022, up 5.8% quarter-over-quarter.
  • 1 fund opened new Biolase, Inc. positions in Q3 2022 and 0 closed out, a net change of +1 holder.
  • The largest Biolase, Inc. buyer in Q3 2022 was Armistice Capital, an estimated $211K added.
  • The largest Biolase, Inc. seller in Q3 2022 was Morgan Stanley, an estimated $62.4K sold.

Based on aggregated 13F filings for Q3 2022.